Kaken Pharmaceutical Co., Ltd. entered into a purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for approximately $100 million on December 19, 2024.

His research has focused on diverse therapeutic modalities that target cancer vulnerabilities, modulate the immune system and deliver cytotoxic payloads to cancer cells ... Read More

We believe success depends on addressing the limitations of current mTOR inhibitors and leveraging the latest genomic profiling technology to identify the patients most likely to benefit from mTOR inhibition.

MORRISTOWN, N.J. - Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), a preclinical stage oncology therapeutics company with a current market capitalization of $48 million, announced today the completion...

Whitehawk Therapeutics is a preclinical stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments.

Note:Kaken will advance KP-723, an oral STAT6 inhibitor, to the completion of PⅠ trials, which had entered into a license agreement with J&J. Note: Development of Tildacerfont, a treatment for congenital adrenal hyperplasia, has been discontinued.

Aadi Bioscience (NASDAQ: AADI) has announced the halt of its PRECISION1 trial for nab-sirolimus in solid tumors with TSC1 or TSC2 alterations due to unlikely regulatory approval.

Beware of Solicitations, Phishing e-mails, and SNS that Fraudulently Use the Name of Kaken Pharmaceutical

In December 2025, Palvella announced positive topline efficacy results from the Phase 2 TOIVA study, achieving statistical significance on multiple pre-specified clinician-reported and patient-reported efficacy endpoints, including dynamic change endpoints and static severity endpoints.

Orchestra BioMed has additional product candidates and plans to potentially expand its product pipeline through acquisitions, strategic collaborations, licensing, and organic development.